

#### Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables

#### V. The Controlled Extraction Study

PQRI Leachables & Extractables Working Group PQRI Training Course 12-13 April 2007 Chicago, IL

#### Definition

A Controlled Extraction Study is a laboratory investigation into the qualitative and quantitative nature of extractable profiles from critical components of an OINDP container/closure system

> PQRI Safety Thresholds and Best Practices for Extractables and Leachables in OINDP November 2005

#### **Top Ten Reasons Why Controlled Extraction Studies are Needed**

- To make an informed selection > To evaluate the safety of the of materials.
- To meet regulatory expectations.
- To control leachables.
- To control materials from lot to lot.
- To correlate extractables data to leachables.

- materials.
- To predict worst case of endof shelf life leachables.
- To qualify packaging materials.
- To obtain a comprehensive extractables profile.
- Because USP testing does not provide applicable data.

#### **Course Objectives**

Purpose of a Controlled Extraction Study
 PQRI Best Practice Recommendations
 Controlled Extraction Study Example Data
 Qualitative and Quantitative Profiles
 Method Optimization
 Conclusion

The Purpose of a Controlled Extraction Study is to systematically and rationally identify and quantify potential leachables, to the extent practical, and within certain defined analytical threshold parameters.

#### Utility of Extractable Information

Obtain Data for Risk Assessment § Provide Information to Toxicologists for **Preliminary Risk Assessment §** Apply Threshold Principles Provide Basis for Leachable Methods Correlate Extractable Data to Leachables Data Develop Routine Extractable Tests Establish Control Criteria

## Study Strategy

► When to Begin § Early in Development Phase Establish Team and Obtain Extractable Information ► Where to Begin § Select Critical Components ► Knowledge of Materials **§** Extraction Solvents/Techniques **§** Analytical Methods Where to End § Application of the AET § Identification Categories S Data Evaluation and Reporting **§** Control of Leachables

## **Critical Components**

 MDI, DPI, Nasal Inhalation Solutions and Sprays
 Patient Contact
 Product Contact
 Device Performance
 Secondary Packaging
 Ancillary Components

## **Typical Materials**

#### OINDP Components

- § Valves (Gaskets/O-rings)
- § Mouthpiece
- § Canister
- **§** Secondary Packaging
- **§** Pump Components
- **§** Actuator
- **§** Containers
- **§** Blisters
- § Labels/Adhesives/Inks

- Extractables (0.01-1000ug)
  - § Solvents
  - § Monomers/Dimers/Trimers
  - **§** Curatives
  - S Photo Initiators
  - **§** Plasticizers
  - § Lubricants
  - **§** Processing Aids
  - § Antioxidants
  - **§** Cleaning Residues
  - § Reaction/Degradation and Breakdown Products

#### Knowledge of Materials/Processes

Materials of Composition
Base Material
Additives and Processing Aids
Polymerization Process
Fabrication process
Cleaning and Pretreatment
Component Storage and Shipping

#### **Extractable Profiles**

Oualitative
Comprehensive
Ouantitative
Worst Case Leachables
Component Control
Acceptance Criteria

## Challenges/Choices

- What Components?
- How Many Components ?
- What Volume of Solvent?
- What Reference Material Should be Selected?
- What Solvents?
- What Extraction Techniques?
- What Analysis Conditions?

#### Considerations

Extraction should be vigorous, but not so aggressive as to alter the qualitative and/or quantitative nature of the extractable profile
 Must be technically justified and optimized to produce extractables profiles at least equivalent to leachable profiles obtained under worst case conditions

Jenke, DR. PDA J Pharm Sci Technology, 2003


# PORI Best Practices Recommendations

**Ten Principal Objectives** 


#1 Controlled Extraction Studies should employ vigorous extraction with multiple solvents of varying polarity.

Range of Polarities
Range of Boiling Points
One of Similar Extracting Properties to Drug Product Vehicle
Relatively Non-reactive
High Purity
Easily and Safely Handled
Readily Available


## Solubility



## Thermolysis



## **Extractable Yield**



# #2 Controlled Extraction Studies should incorporate multiple extraction techniques.







PQRI Trainir

April 2007


## Sulfur Cured Elastomer



#### **Peroxide- Cured Elastomer**



## Polypropylene



#3 Controlled Extraction Studies should include careful sample preparation based on knowledge of analytical techniques to be used.

Preparation of Extracts

 § Sampling, Sample:Surface Ratio, Solvents, Conditions


 Test Sample Preparations

 § Instrumental Techniques
 § Concentration/Dilution

April 2007

**PQRI** Training Course

#### Sample Introduction



Reconstituted in Methylene Chloride


2- Propanol Extract

April 2007


**PQRI** Training Course

#### Artifacts


#### 2-(chloromethylthio)benzothiazole



## Solvent Compatibility



#### Solvent Compatibility




#### #4 Controlled Extraction Studies should employ multiple analytical techniques

- Gas Chromatography/Mass Spectrometry (GC/MS)
- Liquid Chromatography/Mass Spectrometry (LC/MS)
- Liquid Chromatography/Diode Array Detection (LC/DAD)
- Gas Chromatography/Flame Ionization Detection (GC/FID)
- Liquid Chromatography/Ultraviolet Detection (LC/UV)
- Fourier Transform Infrared Spectroscopy (FTIR)
- Inductively Coupled Plasma/Mass Spectroscopy (ICP/MS)
- Inductively Coupled Plasma/Optical Emission Spectroscopy (ICP/OES)
- Scanning Electron Microscopy. Energy Dispersive X-Ray "(SEM/EDX)


#### Qualitative System Suitability

Compound	Suggested Technique	Recommended Target Concentration (ug/ml)
2-Mercaptobenzothiozole	GC or LC	50
Tetramethylthiuramdisulfide	GC or LC/UV	50
Butylatedhydroxytoluene	GC or LC	50
Irganox 1010	LC	50
Diphenyl Amine	LC	50
Bis-(2-ethylhexyl) phthalate	GC or LC	50
Bis (dodecyl) phthalate	GC or LC	.50
Stearic Acid	GC or LC/MS	100
2-ethylhexanol	GC	50
Pyrene April 2007	GC or LC/UV PQRI Training Course	1 29




GC/MS of polypropylene 2-propanol extract: 1 = 2,6-di-methyl benzaldehyde; 2 = 2,4-di-*tert*-butylphenol; 3 =glycerol monostearate. PQRI Training Course 30


#### **Complimentary Techniques**



## **Compound Specific Detection**



#5 Controlled Extraction Studies should include a defined and systematic process for identification of individual extractables



## Identification Categories

#### <u>Confirmed:</u>

- § Mass spectrometric fragmentation behavior
- § Confirmation of molecular weight or confirmation of elemental composition
- § Mass spectrum matches automated library or mass spectrum and chromatographic retention index match authentic specimen

#### Confident:

§ Sufficient data to preclude all but the most closely related structures have been obtained


#### <u>Tentative:</u>

§ Data have been obtained that are consistent with a class of molecule only

April 2007


**PQRI** Training Course

#### Confirmed Peak 21.47 min 2,2'-methylene-bis-(-6-*tert*-butyl)-4-ethylphenol Confirmation of Molecular Weight; Fragmentation Behavior; Mass Spectral Library Match; RT Match to Authentic Standard




#### Confirmed Peak 21.47 min

#### 2,2'-methylene-bis-(-6-tert-butyl)-4-ethylphenol




### Confident Peak 8.15 min Benzothiazole

Mass Spectrometric Fragmentation Behavior; Mass Spectrum Matches Automated Library Search




### Confident Peak 8.15 min Benzothiazole






Tentative Peak 15.05 min Coumarone-indene resin related

Confirmation of Elemental Composition; Mass Spectrometric Fragmentation Behavior



### Tentative Peak 15.05 min Coumarone-indene resin related

#### Abundance



#6 Controlled Extraction Study "definitive" extraction methods should be optimized.


Asymptotic Levels
 Represent at Least Worst Case Leachables

 Qualitative
 Quantitative

 Verification of Quantitative Results
 Basis for Development and Validation of Routine Extractable Control Methods

### **Sulfur Cured Rubber**

Analysis: GC/MS Extraction: Soxhlet Optimization: 7g/200ml Methylene Chloride 10:1 Dilution Internal Standard 16 Hours Extraction



## Polypropylene

Extraction: Reflux

Analysis:

**Optimization:** 

**Results:** 


HPLC/UV

Solvent to Sample Ratio Analyte Solubility/Standardization Asymptotic Extraction Chromatography Conditions


1g:25ml (50/50 THF/IPA) 3 Hr Extraction


April 2007

# Polypropylene



## Polypropylene





April 2007

## Example Chromatography Conditions

#### Qualitative



#### LC/MS

Column:	C18, 4.6mmx25cm, 5u
Injection Vol:	10ul (1/mL/min)
Mobile Phase:	<a> 75:25 (ACN:H20)</a>
	<b> 50:50 (ACN:THF)</b>
Gradient:	30 min. gradient at 100%
	A to 100% B hold 12 min
Ionization:	APCI
Scan:	m/z 50-1350 ,5 sec/scan

#### HPLC/DAD Column: C18, 4.6mmx25cm, 5u @ 60C Injection Vol: 10ul (1/mL/min) Mobile Phase: <A> ACN <B> H2O Gradient: 25 min. linear gradient at 30:70 A:B to 100% A hold 5min Detector: Diode Array Detector 200nm, 220nm, bw/4nm; ref.sig 550nm, bw/100nm

## Quantitation

#### Internal Standard

- $\mathsf{RRF} = (\mathsf{A}_{\mathsf{a}}\mathsf{C}_{\mathsf{i}})/(\mathsf{A}_{\mathsf{i}}\mathsf{C}_{\mathsf{a}})$ 
  - §  $A_a =$  Area of Analyte Peak
  - C<sub>i</sub> = Concentration of Internal Standard
  - § A<sub>i</sub> = Area of Internal Standard Peak
  - §  $C_a = Concentration of Analyte$

Concentration in Sample Extract
 C<sub>a</sub> = A<sub>a</sub>x C<sub>i</sub>/A<sub>i</sub>x RRF

Total mass =  $C_aug/ml x$  Vol of extract

 Extractable in Component µg/g Extractable = Total mass (µg)/g Component

#### **External Standard**

 $RF = C_s / A_s$ 

- S C<sub>s</sub> = Concentration of External Standard
- **§** A<sub>s</sub>= Area of External Standard
- Concentration in Sample Extract
   C<sub>a</sub> = A<sub>a</sub>x RF

Total mass =  $C_aug/ml x$  Vol of extract

Extractable in Component
 µg/g Extractable =
 Total mass (µg)/g Component

## System Suitability Example

Instrument Precision (%RSD)	≤ 10	
Resolution (n=6)	≥ 2	
Tailing Factor (n=6)	≤ 2	
Sensitivity (S/N of MQL)	≥ 10	
Method Repeatability (%RSD)	≤ 10%	
Intermediate Precision (%RSD)	≤ 10%	
Recovery	80-120%	

April 2007

### **Method Validation**

#### Acceptance Criteria

- § System Suitability
- **§** Instrument Precision
- § Chromatographic Resolution
- S Chromatographic Tailing Factor
- § Linearity/Range
- § Precision
  - Method Repeatability
  - Standard Sample Stability
- **§** Intermediate Precision
- **§** Specificity
- § Accuracy

§ Limit of Quantitation/Limit of Detection

April 2007 **S** Robustness/Ruggedness

#7 During the Controlled Extraction Study process, sponsors should revisit supplier information

#### Investigate


S Chemical entities found in the extractable data not included in supplier information

§ Known chemical entities not detected in the extractable

### **Extractable Data**

Code Letter	Qualitative Results	Supplier Information	Quantitative Results
С	Tetrakis (methylene(3,5-di-t-butyl-4- hydroxyhyrocinnate)) methane	Phenolic Antioxidants 0.08 %	0.059%
В	Bis(2,4-di-t-butylphenyl)pentaerythritol disphosphite and di-tert butylphenol	Phosphite Antioxidant 0.05%	0.045%
	Calcium Stearate	Stearate Mould Release 0.03 – 0.4%	Not Detected
	Glycerol monopalmitate/monostearate	Vegetable oil 0.2 - 0.3 %	Not Detected
	Tetradeconoic, Hexadecanoic and Octadecanoic Acids	N/A	N/A
А	3,4-dimethyldibenzylidene sorbitol	Clarifier 0.2 - 0.3 %	0.14
April 2007	April 2007 PQRI Training Course		

### **Known Accelerator**



**GC-MS of Methylene Chloride Soxhlet Extract** 

#8 Controlled Extraction Studies should be guided by an Analytical Evaluation Threshold (AET) that is based on an accepted safety evaluation threshold

How low to go to identify and evaluate individual extractable

## **AET Extractables**

A leachable dose less than or equal to the SCT is a dose so low that there would be negligible safety concerns from toxic effects. § Internal or External Standards can be employed to Measure the SCT level. S The sensitivity needed for the extractable and leachable methods can be postulated. S Comprehensive extractable studies can be predictive of end of shelf life leachable studies

## 1<sup>st</sup> Application of the Analytical Evaluation Threshold (AET)

#### Example Nasal Spray Component #1:

4 doses per day 120 doses per container 0.15g tube
Estimate AET: (Tox Assessment Value) Convert SCT (0.15 µgTDI) to µg/container
0.15 µg/day X 120 doses/container = 4.5 µg/tube 4 doses/day
4.5µg/tube = 30µg/g 0.15g tube

April 2007

### How are unknowns measured?

#### Estimated

Based on Response of

§ Internal Standard

§ Significant Identified Extractable Peak

► Final

§ Incorporate Uncertainty
 > RRF Data Base
 > One %RSD or 50% of Estimated AET

### **Uncertainty Factor**

#### Final AET

#### Tube (30 ug/g)

50% correction of the estimated AET = 15ug/g Estimated AET corrected for one %RSD (i.e., 35%) =20ug/g

#### What does that mean? Extractables ≥ The Estimated AET should be Identified to the Extent Possible

April 2007

### Location of the AET (Extractables)


#### Extraction

§ 2 grams (100 cm<sup>2</sup>) extracted in 100mL of 2-propanol

> AET

**§** AET response typical of UV antioxidant species

- Final AET
  - § 50% Factor



**#9** Polyaromatic Hydrocarbons (PAH's; or Polynuclear Aromatics, PNA's), N-nitrosamines, and 2-mercaptobenzothiazole (MBT) are considered to be "special case" compounds, requiring evaluation by specific analytical techniques and technology defined threshold

#10 Qualitative and quantitative extractables profiles should be discussed with and reviewed by pharmaceutical development team toxicologists so that any potential safety concerns regarding individual extractables, i.e. potential leachables, are identified early in the pharmaceutical development process

## **Component Profiles**

#### Qualitative

- Sampling and Preparation
- Multiple Solvents
- Sample to Surface Ratio
- Guided by the AET
  - Standard Reference Materials
- Multiple Extraction Techniques
- Multiple Analytical Techniques
  - **§** System Suitabilities

#### Quantitative

- Evaluate Qualitative Profiles
- Optimize Method
  - § Extraction
    - Asymptotic Levels
  - § Analysis Conditions/Calibrations
  - § Method Accuracy/Precision
- Uncertainty
  - **§** Finalize AET
- Correlation
  - § Supplier Information
  - § Leachable Studies

April 2007

### Controlled Extraction Study Summary of Steps

#### Qualitative Profile

#### Determine Extractable AET

§ Convert SCT total daily intake to drug product relative units then associate to the mass of the component

#### Quantitative Profile

- § Selection of Analytes
- § Asymptotic Extractions
- S Linear Dynamic Range
- § Consider Special Case Compounds

Optimize Method and Determine Range and Limits

- § Recovery/Repeatability
- § Based on Techniques used in Controlled Extraction Study

#### Validate Methods

April 2007 What Next?

## **Routine Extractable Testing**

 Test Multiple Component Lots
 Correlate to Leachables
 Establish Specification and Acceptance Criteria
 Component Control

### Science Based Approach

- Define expectation early
- Understand and apply the science involved
- Select appropriate CCS materials and components
- Apply appropriate upstream controls
- Communicate and Collaborate starting in early stages of drug development
  - § With-In company
  - § With suppliers
  - § With regulatory bodies
- PQRI WG proposal seems to support similar approach

Guirag Poochikian PhD. PORI Safety Thresholds and Best Practices for Extractables and Leachables in OINDP PORI Training Course November 2005

#### Summary of PQRI Recommendations

#### Controlled Extraction Studies should:

- § employ vigorous extraction with multiple solvents
- § incorporate multiple extraction techniques
- § include careful sample preparation based on knowledge of analytical techniques to be used
- § employ multiple analytical techniques
- § define a systematic process for identification of individual extractables
- § optimize definitive extraction techniques/methods
- § be evaluated relative to supplier information describing formulation
- s consider special case (PNA, MBT and nitrosoamines) separately
- § review profiles with development team toxicologists to be alerted to safety concerns regarding individual extractables

## Conclusion

- Extraction techniques/methods used for Controlled Extraction Studies must be technically justified and optimized to produced extractable profiles at least equivalent to leachable profiles obtained under worst case conditions of drug product use, allowing both qualitative and quantitative extractable leachable correlations
- Properly conducted Controlled Extraction Studies, when accomplished early in the pharmaceutical development process, permit a pharmaceutical development team to begin early evaluation of potential drug product leachables. This evaluation can alert the pharmaceutical development team to potential leachables with toxicological concern, allowing adequate time to begin appropriate safety qualification studies, or modification of CCS system.

## Conclusion

The Best Practices recommendations for Controlled Extraction studies are not meant to be prescriptive or to exclude other scientifically valid approaches, the analytical techniques/methods, or control strategies

These recommendations represent a consensus with-in the Working Group on current best practices with-in the pharmaceutical industry and are designed to reduce the level of uncertainty with-in the pharmaceutical development process for OINDP

April 2007

### References

Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulation; Draft Guidance for Industry US Department of Health and Human Services FDA CDER/CBER/CVM/ORA, September, 2004

Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products: Chemistry Manufacturing and Control Documentation; Draft Guidance for Industry; US Department of Health and Human Services Food and Drug Administration CDER; October 1998

Nasal Spray Inhalation Solution, Suspension, and Spray Drug Products: Chemistry Manufacturing and Control Documentation, Guidance for Industry; US Department of Health and Human Services FDA CDER; July 2002,

Draft Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products; and Experimental Protocols for Controlled Extraction Studies; PQRI Leachables and Extractables Working Group; Submitted July, 2006 PQRI Training Course 68

### References

- PQRI Leachable Extractable Work Shop Presentations; December 2005, <u>www.pqri.org</u>
  - Schroeder, A.; Leachables and Extractables in OINDP: An FDA Perspective
  - S Poochikian, G.; Best Practice Recommendations: Science and Process
  - **§** Ball, D; Derivation and Justification of Safety Thresholds
  - § McGovern, T.; Safety Recommendations: Science and Process
  - **§** Feinburg, T.; Controlled Extraction Studies
  - § Norwood,D.; Development and Application of the Analytical Evaluation Threshold
  - **§** Paskiet, D.; Leachable Studies and Routine Extraction Studies
  - **§** Winkle, H.N.; Direction for Leachables and Extractables

## References

ASTM Designation: D 5524-94 "Standard Test Method for Determination of Phenolic Antioxidants in high Density Polyethylene Using liquid Chromatography"

J.D. Vargo and K.L. Olson "Characterization of Addtives in Plastics by Liquid Chromatography-Mass Spectrometry," J. Chrom., pp.215-224 (1986)

Jenke, DR. Nomenclature Associated with Chmeical Characterization of and Compatibility Evaluations of Medical Product Delivery Systems. PDA J Pharm Sci Technology, 57 (2), pp. 97-108, 2003